Motonobu Saito

23PUBLICATIONS
109CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersEpidemiological methodsEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 15, 2026
Longitudinal Changes in Nutritional, Inflammatory, and CT-Derived Body Composition Markers During Adjuvant Chemotherapy for Stage II/III Colorectal Cancer.

|Jan 10, 2026
Evaluation of NTRK Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma.

Tomoyuki Momma, Motonobu Saito, Shotaro Nakajima

|Nov 27, 2025
KRAS G12A Identifies a High-Risk Subset in Resected Stage II-III Colorectal Cancer.

Tomoyuki Momma, Hirokazu Okayama, Sohei Hayashishita

|Sep 09, 2025
Extracellular vesicles of cancer cells induce FOXP3+ fibroblasts and facilitate tumor invasion via the Wnt3-β-catenin pathway.

Tomoaki Kimura, Kurara Takagane, Go Itoh

|Aug 18, 2025
GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.

Hiroya Suzuki, Hirokazu Okayama, Shotaro Nakajima

|Aug 13, 2025
Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer.

Hajime Matsuida, Kosaku Mimura, Shotaro Nakajima

Pageof 4

Frequent Collaborators

13 joint publications

Hirokazu Okayama

12 joint publications

Kosaku Mimura

7 joint publications

Shotaro Nakajima

3 joint publications

Tomoyuki Momma